Becton Dickinson and Co vs Centrus Energy Corp — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Centrus Energy Corp trades at $189.91 (market cap $3.78B). The key difference: Becton Dickinson and Co is far larger — about 12.9× Centrus Energy Corp's market cap, and Becton Dickinson and Co pays a 2.34% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals.
| BDX | LEU | |
|---|---|---|
Market Cap | $48.93B | $3.78B |
Sector | Health | Energy |
52-Week High | $185.39 | $436.00 |
52-Week Low | $138.62 | $146.61 |
Enterprise Value | $65.03B | $3.09B |
Dividend Yield | 2.34% | — |
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Centrus Energy (LEU) trades at $191.37, up 7.49% in 24 hours, showing strong momentum amid bullish technical signals. Recent Q2 2026 earnings beat expectations with EPS of $0.77 versus $0.732 expected, though revenue growth is tempered by margin compression. The company secured a $900 million DOE contract and expanded its backlog to $4.5 billion, positioning it for long-term nuclear fuel demand. Analysts maintain a consensus buy rating with a $228.50 price target, reflecting optimism in its HALEU market dominance.
Outlook is positive due to government support and backlog visibility, but risks include high valuation (P/E 68.23), volatile cash flows, and execution challenges in scaling production. Investors should weigh growth potential against cost pressures and competitive dynamics in the nuclear sector.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →